Drug intelligence / Profile preview

6-mercaptopurine + azathioprine + mesalamine

Development stage: Unknown
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral, Rectal

Overview

A combination therapy used in the treatment of inflammatory bowel disease (IBD), particularly Crohn's disease and ulcerative colitis. This combination involves thiopurine drugs (6-mercaptopurine and azathioprine) with mesalamine (5-aminosalicylic acid). When co-administered, these medications have important pharmacokinetic interactions, with mesalamine increasing blood levels of 6-thioguanine nucleotide (6-TGN), a metabolite of thiopurines, which can lead to increased efficacy but also higher risk of leucopenia.

Targets

TPMT (Thiopurine S-methyltransferase)15-LOX (Lysyl Oxidase)COX

Beyond the preview

Go deeper on 6-mercaptopurine + azathioprine + mesalamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 6-mercaptopurine + azathioprine + mesalamine.

Explore the full profile